Foghorn Therapeutics (FHTX) EBT Margin (2020 - 2026)

Foghorn Therapeutics' EBT Margin history runs 7 years deep, the most recent figure standing at 2468.38% for Q1 2026.

• In Q1 2026, EBT Margin fell 208224.0% year-over-year to 2468.38%; the TTM figure through Mar 2026 stood at 800.84% (down 44096.0% YoY), while the FY2025 annual figure was 858.26%, down 47502.0% from the prior year.
• EBT Margin for Q1 2026 stood at 2468.38%, down from 257.91% in the prior quarter.
• The five-year high for EBT Margin was 77.85% in Q3 2023, with the low at 2468.38% in Q1 2026.
• The 5-year median for EBT Margin is 509.82% (2023), against an average of 608.57%.
• The sharpest annual moves came in 2022 and 2026: EBT Margin jumped 24430424 bps in 2022, then tumbled 208224 bps in 2026.
• Foghorn Therapeutics' EBT Margin stood at 690.39% in 2022, then soared by 44 bps to 383.43% in 2023, then tumbled by 78 bps to 682.88% in 2024, then jumped by 62 bps to 257.91% in 2025, then tumbled by 857 bps to 2468.38% in 2026.
• Business Quant data shows FHTX's EBT Margin at 2468.38% in Q1 2026, 257.91% in Q4 2025, and 512.09% in Q3 2025.